Abstract
During the 2013-2016 Ebola virus (EBOV) outbreak in West Africa, our team at USAMRIID evaluated the antiviral activity of a number of compounds, including favipiravir (T-705), in vitro and in mouse and nonhuman primate (NHP) models of Ebola virus disease. In this short communication, we present our findings for favipiravir in cell culture and in mice, while an accompanying paper presents the results of NHP studies. We confirmed previous reports that favipiravir has anti-EBOV activity in mice. Additionally, we found that the active form of favipiravir is generated in mice in tissues relevant for the pathogenesis of EBOV infection. Finally, we observed that protection can be achieved in mice down to 8 mg/kg/day, which is lower than the dosing regimens previously reported. An accompanying paper reports the results of treating nonhuman primates infected with EBOV or with Marburg virus with oral or intravenous favipiravir.
Citations
Jul 10, 2018·The Journal of Infectious Diseases·Md N RahimXiangguo Qiu
Feb 6, 2019·Viruses·Jason E ComerAlexander N Freiberg
Feb 12, 2019·Scientific Reports·Thomas M BocanRolf E Swenson
Nov 16, 2018·Journal of Medical Virology·Muhammad Usman MirzaMuhammad Idrees
Feb 23, 2020·Virus Genes·J J BugertA Brancale
May 4, 2020·Journal of Neurology·Peter J RichardsonMario Corbellino
Oct 6, 2020·SN Comprehensive Clinical Medicine·Shweta JakhmolaHem Chandra Jha
Oct 3, 2018·Nature Communications·Vincent MadelainJérémie Guedj
Dec 11, 2020·Antiviral Chemistry & Chemotherapy·Johanna Huchting
Dec 30, 2020·Expert Review of Anti-infective Therapy·Seyed MohammadReza HashemianAli Akbar Velayati
Dec 7, 2019·Journal of Autoimmunity·Manuel RojasJuan-Manuel Anaya
Feb 18, 2021·Expert Opinion on Investigational Drugs·Frederick HansenMichael A Jarvis
Jun 3, 2021·The Journal of Antimicrobial Chemotherapy·Henry PertinezAndrew Owen
Jun 8, 2021·Chemical Science·Eleni E LitsaLydia E Kavraki
Aug 11, 2021·Viruses·Olivier EscaffreJason E Comer
Jun 16, 2018·Journal of Medicinal Chemistry·Johanna HuchtingChris Meier